Resource Summary Report

Generated by PRECISE-TBI on Aug 24, 2026

CD4 Monoclonal Antibody (S3.5), Qdot™ 655

RRID:AB_11180600
Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# Q10007, RRID:AB_11180600

Antibody Information

URL: http://antibodyregistry.org/AB_11180600

Proper Citation: Thermo Fisher Scientific Cat# Q10007, RRID:AB_11180600

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow (Assay-dependent)

Antibody Name: CD4 Monoclonal Antibody (S3.5), Qdot™ 655

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: Clone S3.5

Defining Citation: PMID:21148512, PMID:24999737, PMID:21825174, PMID:22679502

Antibody ID: AB_11180600

Vendor: Thermo Fisher Scientific

Catalog Number: Q10007

Record Creation Time: 20250819T230719+0000

Record Last Update: 20250820T042118+0000

Ratings and Alerts

No rating or validation information has been found for CD4 Monoclonal Antibody (S3.5), Qdot™ 655.

No alerts have been found for CD4 Monoclonal Antibody (S3.5), Qdot™ 655.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at PRECISE-TBI .

Rosenbaum E, et al. (2026) Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1777.

Comen E, et al. (2024) Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer. iScience, 27(2), 108880.

Castell NJ, et al. (2024) SIV-specific antibodies protect against inflammasome-driven encephalitis in untreated macaques. Cell reports, 43(10), 114833.

Zappasodi R, et al. (2018) Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell, 33(6), 1017.

Naing A, et al. (2018) PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer cell, 34(5), 775.